<DOC>
	<DOCNO>NCT02516618</DOCNO>
	<brief_summary>The primary objective study assess safety tolerability single dose subcutaneous ( SC ) intravenous ( IV ) administer fasinumab healthy Japanese subject .</brief_summary>
	<brief_title>Study Fasinumab ( REGN475 ) Healthy Japanese Caucasian Subjects</brief_title>
	<detailed_description />
	<criteria>Key 1 . Healthy male female Japanese Caucasian volunteer ≥20 ≤55 year age screen visit 2 . Japanese subject must : Be first generation Japanese , define born Japan 4 biologic grandparent ethnic Japanese Have maintain Japanese lifestyle since leave Japan 3 . Caucasian subject must Caucasian European Latin American descent 4 . Have Body Mass Index ( BMI ) ≤ 35 5 . Be willing refrain take NSAID medication ( oral topical ) 1 week prior receive study drug 16 week study drug administration Key 1 . History presence screen visit bone joint disorder include limited osteoarthritis , avascular necrosis , destructive arthropathy , pathologic fracture , osteonecrosis , rheumatoid arthritis , neuropathic joint arthropathy , lupus erythematosus , inflammatory joint disease 2 . History jointrelated event , limit , total joint replacement ( TJR ) surgery , patella dislocation , hip dislocation , knee dislocation , injury meniscus knee ligament ( without surgical repair ) , joint infection 3 . Trauma joint 30 day prior screen visit 4 . History autonomic neuropathy , diabetic neuropathy 5 . Evidence autonomic neuropathy 6 . Presence clinically relevant peripheral neuropathy 7 . History presence screen visit orthostatic hypotension 8 . History evidence screen heart block 9 . Resting heart rate &lt; 50 &gt; 100 beat per minute ( bpm ) 10 . History poorly control hypertension : 11 . Congestive heart failure NY Heart Classification stage 3 4 12 . History myocardial infarction , acute coronary syndrome , cerebrovascular accident within 12 month prior screen visit 13 . Significant concomitant illness , limited , cardiac , renal , neurological , endocrinological , GI , hepatic , metabolic lymphatic disease would adversely affect subject 's participation study interpretation safety/PK data 14 . HIV , hepatitis B , hepatitis C positive serological test screen visit 15 . History presence malignancy within 5 year prior screen , except subject treat successfully recurrence basal squamous cell carcinoma skin ( &lt; 1 year ) , situ cervical cancer , situ ductal breast cancer 16 . Women reproductive potential positive serum pregnancy test result screen visit , positive urine pregnancy test result baseline visit , pregnancy test result baseline visit 17 . Pregnant breastfeed woman 18 . Participation clinical research study evaluate another investigational drug therapy within 30 day least 5 halflives investigational drug , whichever longer , prior day 1 visit</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>